The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Small Molecule Ligands of the BET-like Bromodomain, Sm BRD3, Affect Schistosoma mansoni Survival, Oviposition, and Development
Open accessPublished version of a preprint
Abstract
Schistosomiasis is a disease affecting over 200 million people worldwide, but its treatment relies on a single agent, praziquantel. To investigate new avenues for schistosomiasis control, we have conducted the first systematic analysis of bromodomain-containing proteins (BCPs) in a causative species, Schistosoma mansoni. Having identified 29 putative bromodomains (BRDs) in 22 S. mansoni proteins, we selected SmBRD3, a tandem BRD-containing BCP that shows high similarity to the human bromodomain and extra terminal domain (BET) family, for further studies. Screening of 697 small molecules identified the human BET BRD inhibitor I-BET726 as a ligand for SmBRD3. An X-ray crystal structure of I-BET726 bound to the second BRD of SmBRD3 [SmBRD3(2)] enabled rationale design of a quinoline-based ligand (15) with an ITC Kd value of 364 ± 26.3 nM for SmBRD3(2). The ethyl ester pro-drug of compound 15 (compound 22) shows substantial effects on sexually immature larval schistosomula, sexually mature adult worms, and snail-infective miracidia in ex vivo assays. This compound will form the basis for future studies into new treatments for schistosomiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Flagged first, then by citations
Research works printed but not linked: 73
- 10.1016/j.ijpara.2012.02.003 · DOI
- 10.1016/j.pt.2016.12.002 · DOI
- 10.1038/s41573-020-0077-5 · DOI
- 10.1016/j.cbpa.2018.06.015 · DOI
- 10.1038/s41594-019-0309-8 · DOI
- 10.1002/anie.201812164 · DOI
- 10.1021/acsinfecdis.1c00387 · DOI
- 10.1371/journal.ppat.1004116 · DOI
- 10.1371/journal.ppat.1005963 · DOI
- 10.1126/science.abb7699 · DOI
- 10.1038/s41572-018-0013-8 · DOI
- 10.1016/j.ijpddr.2018.10.005 · DOI
- 10.1016/j.cell.2012.06.045 · DOI
- 10.1021/acs.jmedchem.2c00453 · DOI
- 10.1016/j.cell.2012.02.013 · DOI
- 10.1016/j.molbiopara.2003.09.005 · DOI
- 10.1016/j.molbiopara.2005.12.006 · DOI
- 10.1016/j.actatropica.2007.11.006 · DOI
- 10.1371/journal.pntd.0007693 · DOI
- 10.1093/nar/gkac240 · DOI
- 10.1093/nar/gkt1223 · DOI · Paper page
- 10.1021/jm300915b · DOI
- 10.1016/j.febslet.2012.04.045 · DOI
- 10.1021/jm200108t · DOI
- 10.1038/nprot.2007.321 · DOI
- 10.1021/jm200640v · DOI
- 10.1021/jm301588r · DOI
- 10.1039/C2MD20189E · DOI
- 10.1002/anie.201402750 · DOI
- 10.1021/ja412434f · DOI
- 10.1002/anie.201602908 · DOI
- 10.1016/j.bmc.2018.05.003 · DOI
- 10.1002/cmdc.202000528 · DOI
- 10.1021/acs.jmedchem.1c00348 · DOI
- 10.1021/acsinfecdis.0c00618 · DOI
- 10.1021/jm5010539 · DOI
- 10.1038/nature09504 · DOI · Paper page
- 10.1016/j.cub.2006.12.037 · DOI
- 10.1021/cb500996u · DOI
- 10.1016/j.bmc.2017.10.042 · DOI
- 10.3390/pharmaceutics15051359 · DOI
- 10.1021/om100106e · DOI
- 10.1021/acs.analchem.6b04060 · DOI
- 10.1021/ac961242d · DOI
- 10.5599/admet.530 · DOI
- 10.1016/j.drudis.2011.06.001 · DOI
- 10.1002/ejoc.201800581 · DOI
- 10.1135/cccc19800517 · DOI
- 10.1021/ol901113t · DOI
- 10.1039/C1MD00201E · DOI
- 10.1007/s12038-016-9600-6 · DOI
- 10.1021/acs.jmedchem.6b01761 · DOI
- 10.1038/nrm.2016.143 · DOI
- 10.1016/j.molbiopara.2016.11.005 · DOI
- 10.1093/bioinformatics/btv362 · DOI
- 10.1101/308213 · DOI
- 10.1371/journal.pntd.0004334 · DOI
- 10.7554/eLife.00768 · DOI
- 10.1371/journal.pntd.0001455 · DOI
- 10.1371/journal.pntd.0005559 · DOI
- 10.1038/srep31150 · DOI
- 10.1016/0014-4894(74)90005-8 · DOI
- 10.1016/j.ijpddr.2018.10.009 · DOI
- 10.1016/j.ejmech.2021.113823 · DOI
- 10.1371/journal.pntd.0008630 · DOI
- 10.1021/acsinfecdis.1c00025 · DOI
- 10.1177/108705719900400206 · DOI · Paper page
- 10.1371/journal.pntd.0001762 · DOI
- 10.1371/journal.ppat.1009828 · DOI
- 10.1371/journal.pntd.0001494 · DOI
- 10.1371/journal.ppat.1007066 · DOI
- 10.1016/j.exppara.2009.12.021 · DOI
- 10.1016/j.exppara.2008.11.010 · DOI
Metadata
- Authors
- Schiedel, M., McArdle, D. J. B., Padalino, G., Chan, A. K. N., Forde-Thomas, J., McDonough, M., Whiteland, H., Beckmann, M., Cookson, R., Hoffmann, K. F., & Conway, S. J.
- Affiliations
- University of Oxford (GB)
- Aberystwyth University (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- University of California, Los Angeles (US)
- Corresponding author
- Hoffmann, Karl F.
- Conway, Stuart J.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2023-12-04
- Volume
- 66
- Issue
- 23
- Pages
- 15801-15822
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- PMC
- PMC10726355
- OpenAlex
- W4389302791
- Cited by
- 4
- References
- 1
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion, cc-by)
- ChemRxiv (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Cronfa (Swansea University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Life Sciences Research Network Wales
- University of California, Los Angeles
- Deutsche Forschungsgemeinschaft (SCHI 1408/1-1)
- GlaxoSmithKline
- Horizon 2020 Framework Programme (660156)
- St. Hugh's College, University of Oxford
- Biotechnology and Biological Sciences Research Council (BB/S507015/1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Immunology and Microbiology › Parasitology › Parasites and Host Interactions
- Health Sciences › Medicine › Epidemiology › Trypanosoma species research and implications
- Keywords
- bromodomain, small-molecule ligands, Schistosoma mansoni, schistosomiasis, parasite survival, oviposition, parasite development, antiparasitic drug discovery
- MeSH terms
- Aminoquinolines, Animals, Benzoates, Female, Humans, Ligands, Oviposition, Schistosoma mansoni, Schistosomiasis, Schistosomiasis mansoni
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review